Kymera Therapeutics (KYMR) director receives stock options on 6,068 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics director Pamela Esposito received a new stock option grant. She was granted options covering 6,068 shares of Kymera Therapeutics common stock at an exercise price of $99.87 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 24, 2027 or the date of the company’s next annual stockholder meeting, aligning vesting with her continued board service. Following this award, Esposito holds derivative securities representing 6,068 underlying common shares according to this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Esposito Pamela
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,068 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,068 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 6,068 shares
Exercise price: $99.87 per share
Post-transaction derivative holdings: 6,068 shares
+3 more
6 metrics
Option grant size
6,068 shares
Stock Option (Right to Buy) underlying common stock
Exercise price
$99.87 per share
Conversion or exercise price of stock option
Post-transaction derivative holdings
6,068 shares
Total shares underlying options following transaction
Vesting date
June 24, 2027
Full vesting or earlier on next annual stockholder meeting date
Option expiration
June 23, 2036
Expiration date of stock option grant
Transaction price per option
$0.00
No cash paid to receive the option grant
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price, vest in full, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 99.8700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The shares underlying this stock option shall vest in full upon the earlier"
annual meeting of the Issuer's stockholders financial
"the date of the next annual meeting of the Issuer's stockholders"
FAQ
What did Pamela Esposito do in this Form 4 for Kymera Therapeutics (KYMR)?
Pamela Esposito reported receiving a stock option grant for 6,068 shares of Kymera Therapeutics common stock. The options were awarded as compensation, not bought in the market, and give her the right to purchase shares at a fixed exercise price.
What is the exercise price of Pamela Esposito’s Kymera Therapeutics options?
The exercise price for the reported Kymera Therapeutics stock options is $99.87 per share. This is the fixed price at which she can buy the 6,068 underlying common shares if she chooses to exercise the options in the future.
When do Pamela Esposito’s Kymera Therapeutics stock options vest?
The options vest in full on the earlier of June 24, 2027 or the date of Kymera Therapeutics’ next annual stockholder meeting. Full vesting must occur before she can exercise the options to acquire the underlying common shares.
How many derivative securities does Pamela Esposito hold after this Kymera grant?
After this transaction, the filing shows Esposito holding derivative securities tied to 6,068 underlying Kymera Therapeutics common shares. This amount equals the newly granted options, indicating the reported position is entirely from this award in the current Form 4.